This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Science 37 Holdings Résultats passés
Passé contrôle des critères 0/6
Science 37 Holdings's earnings have been declining at an average annual rate of -46.3%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 23.9% per year.
Informations clés
-46.3%
Taux de croissance des bénéfices
36.9%
Taux de croissance du BPA
| Life Sciences Croissance de l'industrie | 21.5% |
| Taux de croissance des recettes | 23.9% |
| Rendement des fonds propres | -240.9% |
| Marge nette | -206.9% |
| Dernière mise à jour des bénéfices | 30 Sep 2023 |
Mises à jour récentes des performances passées
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Ventilation des recettes et des dépenses
Comment Science 37 Holdings gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 23 | 60 | -125 | 76 | 0 |
| 30 Jun 23 | 62 | -134 | 86 | 0 |
| 31 Mar 23 | 66 | -121 | 97 | 0 |
| 31 Dec 22 | 70 | -51 | 107 | 0 |
| 30 Sep 22 | 75 | -50 | 121 | 0 |
| 30 Jun 22 | 73 | -41 | 113 | 0 |
| 31 Mar 22 | 66 | -43 | 97 | 0 |
| 31 Dec 21 | 60 | -94 | 76 | 0 |
| 30 Sep 21 | 50 | -42 | 54 | 0 |
| 30 Jun 21 | 43 | -35 | 44 | 0 |
| 31 Mar 21 | 33 | -33 | 38 | 0 |
| 31 Dec 20 | 24 | -32 | 34 | 0 |
| 31 Dec 19 | 14 | -18 | 23 | 0 |
Des revenus de qualité: SNCE is currently unprofitable.
Augmentation de la marge bénéficiaire: SNCE is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SNCE is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.
Accélération de la croissance: Unable to compare SNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: SNCE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-7.9%).
Rendement des fonds propres
ROE élevé: SNCE has a negative Return on Equity (-240.9%), as it is currently unprofitable.